Azacitidine and venetoclax for the treatment of accelerated and blast phase myeloproliferative neoplasms and chronic myelomonocytic leukemia: a case series

Leuk Lymphoma. 2021 Jun;62(6):1525-1527. doi: 10.1080/10428194.2020.1869961. Epub 2021 Jan 15.

Authors

Alejandro Garcia-Horton¹, Dawn Maze¹, Caroline J McNamara¹, Hassan Sibai¹, Vikas Gupta¹, Tracy Murphy¹

Affiliation

¹ Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada.

PMID: 33448888
DOI: 10.1080/10428194.2020.1869961

No abstract available

Publication types

Letter

MeSH terms

Azacitidine* / therapeutic use
Blast Crisis / drug therapy
Bridged Bicyclo Compounds, Heterocyclic / therapeutic use
Humans
Leukemia, Myelomonocytic, Chronic* / drug therapy
Sulfonamides

Substances

Bridged Bicyclo Compounds, Heterocyclic
Sulfonamides
Azacitidine
venetoclax